Shield blood-based assay
Shield blood-based assay has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 14, 2026: “Cell-Free DNA-Based Blood Tests for Colorectal Cancer Screening: Current Advances, Challenges, and Future Perspectives”.
1 paper studies it1 findingUpdated
1 new paper in 30 daysSee all 1 papers on shield blood-based assay
What is shield blood-based assay linked with?
1Studies link shield blood-based assay with 1 measure, most often colorectal cancer detection (1 study).
Colorectal cancer detection
upin humans1
1 study
Colorectal cancer detection
upin humans1
Shield blood-based assay predicts colorectal cancer detection in humans (average-risk screening population in the ECLIPSE study) (83.1% sensitivity for CRC; 13.2% sensitivity for advanced precancerous lesions).
“the Shield blood-based assay demonstrated 83.1% sensitivity for CRC, whereas the sensitivity for advanced precancerous lesions was only 13.2%.”
Reviewaverage-risk screening population in the ECLIPSE study
Diagnostics (Basel, Switzerland)